Telomir Pharmaceuticals, Inc. reports

Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Miami, FL
SEC filing record 1 source field available
Fiscal year end
31 December
Telomir Pharmaceuticals, Inc. has filed 134 SEC EDGAR filings since 03 Apr 2023

SEC filing history

Showing 1-25 of 134 matching filings.

Per page
25
Current page
1
3

3

Filing date
09 Jun 2026
Reporting date
03 Jun 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4

Filing date
22 May 2026
Reporting date
21 May 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4

Filing date
22 May 2026
Reporting date
21 May 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4

Filing date
22 May 2026
Reporting date
21 May 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4

Filing date
22 May 2026
Reporting date
21 May 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4

Filing date
24 Apr 2026
Reporting date
22 Apr 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
DEFA14A File 001-41952

DEFA14A

Filing date
19 Feb 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A File 005-95236

SCHEDULE 13G/A filing

Filing date
12 Feb 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
PRER14A File 001-41952

PRER14A

Filing date
23 Jan 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .